CD274 and non-small cell lung carcinoma: It is known that PD-L1 acts as an immune checkpoint in many solid tumors, including NSCLC [14,15,16,17,18,19,20]; it also known that many tumors successfully overcome the effect of any treatment by generating a new resistant mutation [21,22,23,24].